BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO
Bergen, Norway, 29 May 2018 - BerGenBio ASA (OSE:BGBIO) will host a conference
call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and
biomarker results from its ongoing Phase II development programme with selective
AXL inhibitor bemcentinib. The data will be presented at the Annual American
Society of Clinical Oncology (ASCO) meeting and at a reception hosted by
BerGenBio (details below).
Conference call details:The call will be hosted by BerGenBio senior management and take place on:
Monday, 4 June 2018 at 8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled start using
below phone number and confirmation code 1068189:Norway +47 2100 2608
United Kingdom +44 (0) 330 336 9106
United States +1 323 794 2594
A slide deck presentation to accompany the call will be made available
at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST
on 4 June 2018.Presentations to be made during the annual ASCO meeting:
Saturday 2 June, 6:00 - 8:00 PM CDT, Chicago School of the Art Institute,
Chicago, IL· BerGenBio reception
· New interim Phase II clinical trial data with bemcentinib and selected pre
-clinical data to be discussed by BerGenBio principal investigators and invited
key opinion leaders
· For further details and to receive an invitation, please email to
[email protected]Monday 4 June, 8:00 AM - 11:30 AM CDT, ASCO Annual Meeting, McCormick Center,
Chicago, IL· Interim clinical data from clinical trial ref. BGBC008 - Poster Board: #292,
Abstract 3078
· Interim clinical data from clinical trial ref. BGBC003 - Poster Board: #80,
Abstract 7020
· To be discussed at the Poster Discussion Session. 11:30 AM - 12:45 PM CDT
· Biomarker study - Poster Board: #385, Abstract 2559Monday 4 June, 1:15 PM - 4:45 PM CDT, ASCO Annual Meeting, McCormick Center,
Chicago, IL· Interim clinical data from clinical trial ref. BGBIL006 - Poster Board:
#375, Abstract 9548The posters presented at ASCO will be made available www.bergenbio.comin the
Investors / Presentations section at the time of presentation.-End-
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors as a potential
cornerstone of combination cancer therapy. The Company is a world leader in
understanding the essential role of AXL kinase in mediating aggressive disease,
including immune evasive, drug resistant, metastatic solid and haematological
cancers.BerGenBio’s lead product, bemcentinib (BGB324), is a selective, potent and
orally bio-available small molecule AXL inhibitor in four Company sponsored
Phase II clinical trials in major cancer indications, with read-outs anticipated
during 2018. It is the only selective AXL inhibitor in clinical development.The Company sponsored clinical trials are:
· Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non
-small cell lung cancer (NSCLC)
· Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
· Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
· Bemcentinib as a single agent and combination therapy in acute myeloid
leukaemia (AML) / myeloid dysplastic syndrome (MDS)The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the
lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate bemcentinib with either MEKINIST® (trametinib) plus
TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial
combining bemcentinib with docetaxel in advanced NSCLC.BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with bemcentinib.
This will facilitate more efficient registration trials and support a precision
medicine based commercialization strategy.The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513Media Relations in Norway
Jan Petter Stiff, Crux Advisers
[email protected]
+47 995 13 891International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
[email protected]
+44 207 638 9571Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statementsThis information is subject to the disclosure requirements pursuant
Ekstern link: http://www.newsweb.no/index.jsp?messageId=452366
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180529.OBI.20180529S10
